EFFECT OF RANIBIZUMAB RETREATMENT FREQUENCY ON NEUROSENSORY RETINAL VOLUME IN NEOVASCULAR AMD
暂无分享,去创建一个
Srinivas R Sadda | Pearse A Keane | Alexander C Walsh | P. Keane | S. Sadda | S. Liakopoulos | A. Walsh | K. Chang | Sandra Liakopoulos | Karen T Chang | Renu V Jivrajka | R. Jivrajka
[1] P. Rosenfeld,et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2006, Ophthalmology.
[2] U. Schmidt-Erfurth,et al. Guidance for the treatment of neovascular age-related macular degeneration. , 2007, Acta ophthalmologica Scandinavica.
[3] L. Labree,et al. Errors in retinal thickness measurements obtained by optical coherence tomography. , 2006, Ophthalmology.
[4] Richard F Spaide,et al. INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2006, Retina.
[5] P. Kaiser,et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. , 2007, American journal of ophthalmology.
[6] C. Regillo,et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.
[7] J. Català Mora,et al. Photodynamic Therapy Of Subfoveal Choroidal Neovascularization With Verteporfin. Fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report nº2 , 2003 .
[8] H. Shapiro,et al. Ranibizumab for Neovascular Age-Related Macular Degeneration (AMD): Optical Coherence Tomography (OCT) vs. Visual Acuity (VA) Changes in PIER Study , 2008 .
[9] Irene Barbazetto,et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. , 2003, Archives of ophthalmology.
[10] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[11] R. Bhisitkul,et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.
[12] U. Schmidt-Erfurth,et al. Management of neovascular age-related macular degeneration , 2007, Progress in Retinal and Eye Research.
[13] R. Avery,et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. , 2006, Ophthalmology.
[14] L. Yannuzzi,et al. REBOUND MACULAR EDEMA FOLLOWING BEVACIZUMAB (AVASTIN) THERAPY FOR RETINAL VENOUS OCCLUSIVE DISEASE , 2007, Retina.
[15] K. McColl,et al. Problems related to acid rebound and tachyphylaxis. , 2001, Best practice & research. Clinical gastroenterology.
[16] J. Slakter,et al. RANIBIZUMAB FOR TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2007, Retina.
[17] P. Keane,et al. Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis , 2008, British Journal of Ophthalmology.
[18] R. Spaide. Ranibizumab according to need: a treatment for age-related macular degeneration. , 2007, American journal of ophthalmology.
[19] Paul G. Updike,et al. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. , 2008, Ophthalmology.
[20] Ziqiang Wu,et al. Error correction and quantitative subanalysis of optical coherence tomography data using computer-assisted grading. , 2007, Investigative ophthalmology & visual science.
[21] P. Keane,et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.
[22] William J Feuer,et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.
[23] K. Eng,et al. Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.
[24] Paul G. Updike,et al. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. , 2007, Investigative ophthalmology & visual science.
[25] J. P. Sy,et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. , 2006, Ophthalmology.